Inherited nervous system cancer-predisposing syndrome

Inherited nervous system cancer-predisposing syndrome (Orphanet code 252190) is a broad grouping category that encompasses a collection of rare genetic conditions in which affected individuals carry germline mutations that significantly increase their risk of developing tumors of the nervous system, including both the central and peripheral nervous systems. These syndromes include well-known entities such as neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), schwannomatosis, von Hippel-Lindau disease, Li-Fraumeni syndrome, and other hereditary conditions predisposing to brain tumors, spinal tumors, and peripheral nerve sheath tumors. The nervous system tumors that arise in these syndromes may be benign (such as schwannomas, meningiomas, and neurofibromas) or malignant (such as malignant peripheral nerve sheath tumors, gliomas, and medulloblastomas). Key symptoms vary depending on the specific underlying syndrome but commonly include the development of multiple nervous system tumors, neurological deficits such as hearing loss, vision changes, seizures, pain, weakness, and numbness. Many of these conditions also have extra-neural manifestations affecting the skin (café-au-lait spots, cutaneous tumors), eyes (Lisch nodules, retinal hemangioblastomas), and other organ systems. Age of onset ranges from childhood to adulthood depending on the specific syndrome. Because this is a grouping category rather than a single disease entity, treatment approaches are highly variable and depend on the specific diagnosis. Management typically involves regular surveillance with imaging (MRI), surgical removal of symptomatic or growing tumors, radiation therapy, and in some cases targeted medical therapies. For example, the MEK inhibitor selumetinib has been approved for plexiform neurofibromas in NF1, and bevacizumab has shown efficacy for vestibular schwannomas in NF2. Genetic counseling is essential for affected families, and multidisciplinary care involving neurologists, oncologists, surgeons, and geneticists is recommended.

Common questions about Inherited nervous system cancer-predisposing syndrome